Potential role of the bitter taste receptor T2R14 in the prolonged survival and enhanced chemoresponsiveness induced by apigenin

Stern,Louisa; Boehme,Lukas Fabian; Goetz,Mara Rebecca; Nitschke,Christine; Giannou,Anastasios; Zhang,Tao; Güngör,Cenap; Reeh,Matthias; Izbicki,Jakob Robert; Fliegert,Ralf; Hausen,Anne; Giese,Nathalia; Hackert,Thilo; Niv,Masha Y.; Heinrich,Stefan; Gaida,Matthias Martin; Ghadban,Tarik

doi:10.3892/ijo.2022.5454

Potential role of the bitter taste receptor T2R14 in the prolonged survival and enhanced chemoresponsiveness induced by apigenin

Authors:
- Louisa Stern
- Lukas Fabian Boehme
- Mara Rebecca Goetz
- Christine Nitschke
- Anastasios Giannou
- Tao Zhang
- Cenap Güngör
- Matthias Reeh
- Jakob Robert Izbicki
- Ralf Fliegert
- Anne Hausen
- Nathalia Giese
- Thilo Hackert
- Masha Y. Niv
- Stefan Heinrich
- Matthias Martin Gaida
- Tarik Ghadban
View Affiliations

Affiliations: Department of General, Visceral and Thoracic Surgery, University Medical Center Hamburg‑Eppendorf, D‑20246 Hamburg, Germany, Section of Molecular Immunology und Gastroenterology, I. Department of Medicine, University Medical Center Hamburg‑Eppendorf, D‑20246 Hamburg, Germany, Department of Biochemistry and Molecular Cell Biology, University Medical Center Hamburg‑Eppendorf, D‑20246 Hamburg, Germany, Institute of Pathology, University Medical Center Mainz, D‑55131 Mainz, Germany, Department of General, Visceral and Transplantation Surgery, University Hospital Heidelberg, D‑69120 Heidelberg, Germany, The Institute of Biochemistry, Food Science and Nutrition, The Robert H Smith Faculty of Agriculture, Food and Environment, The Hebrew University of Jerusalem, 76665 Rehovot, Israel, Department of Surgery, University Medical Center Mainz, D‑55131 Mainz, Germany
Published online on: November 15, 2022 https://doi.org/10.3892/ijo.2022.5454
Article Number: 6
Copyright: © Stern et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Bitter taste receptors (T2Rs) are G protein‑coupled receptors originally detected in the gustatory system. More recently, T2Rs have been shown to be expressed in extra‑oral cells eliciting non‑gustatory functions. Emerging evidence has suggested a potential role for T2R signaling in diverse pathophysiological conditions, including cancer. The aim of the present study was to evaluate the expression of T2R14 in pancreatic ductal adenocarcinoma (PDAC) and to assess its involvement in the anticancer effects induced by apigenin, a natural ligand of T2R14. For this purpose, T2R14 expression was explored in PDAC tumor tissue and tumor‑derived cell lines. Using the cell lines expressing the highest levels of T2R14, its effects on chemoresponsiveness and migration upon activation with apigenin were investigated in vitro. To the best of our knowledge, the present study was the first to confirm the expression of the T2R family member T2R14 in PDAC. Patients with relatively high levels of T2R14 expression exhibited significantly prolonged overall survival compared with that of patients with low T2R14 expression. Furthermore, novel functions for apigenin were revealed; notably, apigenin was shown to elicit cytotoxic, anti‑migratory and chemosensitizing effects to 5‑fluoruracil (5‑FU) and to 5‑FU, leucovorin, irinotecan and oxaliplatin in pancreatic cancer cells. In conclusion, the present study extended the evidence for the anticancer effects of apigenin and strongly indicated the functional relevance of T2R14 in PDAC, even though their respective underlying pathways appear to be independent of each other.

View Figures

View References

1	Siegel RL, Miller KD, Fuchs HE and Jemal A: Cancer statistics, 2022. CA Cancer J Clin. 72:7–33. 2022.
2	Spadi R, Brusa F, Ponzetti A, Chiappino I, Birocco N, Ciuffreda L and Satolli MA: Current therapeutic strategies for advanced pancreatic cancer: A review for clinicians. World J Clin Oncol. 7:27–43. 2016.
3	Neoptolemos JP, Ghaneh P and Hackert T: Multimodality standard of care treatment of resectable and borderline resectable pancreatic cancer. Hepatobiliary Surg Nutr. 10:714–716. 2021.
4	Wang Z, Li Y, Ahmad A, Banerjee S, Azmi AS, Kong D and Sarkar FH: Pancreatic cancer: Understanding and overcoming chemoresistance. Nat Rev Gastroenterol Hepatol. 8:27–33. 2011.
5	Ducreux M, Cuhna AS, Caramella C, Hollebecque A, Burtin P, Goéré D, Seufferlein T, Haustermans K, Van Laethem JL, Conroy T, et al: Cancer of the pancreas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 26(Suppl 5): v56–v68. 2015.
6	Conroy T, Hammel P, Hebbar M, Abdelghani MB, Wei AC, Raoul JL, Choné L, Francois E, Artru P, Biagi JJ, et al: FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med. 379:2395–2406. 2018.
7	Ding R, Shi J, Pabon K and Scotto KW: Xanthines down-regulate the drug transporter ABCG2 and reverse multidrug resistance. Mol Pharmacol. 81:328–337. 2012.
8	Kwatra D, Venugopal A, Standing D, Ponnurangam S, Dhar A, Mitra A and Anant S: Bitter melon extracts enhance the activity of chemotherapeutic agents through the modulation of multiple drug resistance. J Pharm Sci. 102:4444–4454. 2013.
9	Lyn-Cook BD, Rogers T, Yan Y, Blann EB, Kadlubar FF and Hammons GJ: Chemopreventive effects of tea extracts and various components on human pancreatic and prostate tumor cells in vitro. Nutr Cancer. 35:80–86. 1999.
10	Behrens M and Meyerhof W: Bitter taste receptors and human bitter taste perception. Cell Mol Life Sci. 63:1501–1509. 2006.
11	Adler E, Hoon MA, Mueller KL, Chandrashekar J, Ryba NJ and Zuker CS: A novel family of mammalian taste receptors. Cell. 100:693–702. 2000.
12	Meyerhof W, Batram C, Kuhn C, Brockhoff A, Chudoba E, Bufe B, Appendino G and Behrens M: The molecular receptive ranges of human TAS2R bitter taste receptors. Chem Senses. 35:157–170. 2010.
13	Zehentner S, Reiner AT, Grimm C and Somoza V: The role of bitter taste receptors in cancer: A systematic review. Cancers (Basel). 13:58912021.
14	Jeruzal-Swiatecka J, Fendler W and Pietruszewska W: Clinical role of extraoral bitter taste receptors. Int J Mol Sci. 21:51562020.
15	Gaida MM, Mayer C, Dapunt U, Stegmaier S, Schirmacher P, Wabnitz GH and Hänsch GM: Expression of the bitter receptor T2R38 in pancreatic cancer: Localization in lipid droplets and activation by a bacteria-derived quorum-sensing molecule. Oncotarget. 7:12623–12632. 2016.
16	Gottesman MM, Fojo T and Bates SE: Multidrug resistance in cancer: Role of ATP-dependent transporters. Nat Rev Cancer. 2:48–58. 2002.
17	Stern L, Giese N, Hackert T, Strobel O, Schirmacher P, Felix K and Gaida MM: Overcoming chemoresistance in pancreatic cancer cells: Role of the bitter taste receptor T2R10. J Cancer. 9:711–725. 2018.
18	Vivanco I and Sawyers CL: The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer. 2:489–501. 2002.
19	Mundi PS, Sachdev J, McCourt C and Kalinsky K: AKT in cancer: New molecular insights and advances in drug development. Br J Clin Pharmacol. 82:943–956. 2016.
20	Mo W and Zhang JT: Human ABCG2: Structure, function, and its role in multidrug resistance. Int J Biochem Mol Biol. 3:1–27. 2012.
21	Doyle L and Ross DD: Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene. 22:7340–7358. 2003.
22	Medapati MR, Singh N, Bhagirath AY, Duan K, Triggs-Raine B, Batista EL Jr and Chelikani P: Bitter taste receptor T2R14 detects quorum sensing molecules from cariogenic Streptococcus mutans and mediates innate immune responses in gingival epithelial cells. FASEB J. 35:e213752021.
23	Medapati MR, Bhagirath AY, Singh N, Schroth RJ, Bhullar RP, Duan K and Chelikani P: Bitter taste receptor T2R14 modulates gram-positive bacterial internalization and survival in gingival epithelial cells. Int J Mol Sci. 22:99202021.
24	Hariri BM, McMahon DB, Chen B, Freund JR, Mansfield CJ, Doghramji LJ, Adappa ND, Palmer JN, Kennedy DW, Reed DR, et al: Flavones modulate respiratory epithelial innate immunity: Anti-inflammatory effects and activation of the T2R14 receptor. J Biol Chem. 292:8484–8497. 2017.
25	Singh N, Chakraborty R, Bhullar RP and Chelikani P: Differential expression of bitter taste receptors in non-cancerous breast epithelial and breast cancer cells. Biochem Biophys Res Commun. 446:499–503. 2014.
26	Singh N, Shaik FA, Myal Y and Chelikani P: Chemosensory bitter taste receptors T2R4 and T2R14 activation attenuates proliferation and migration of breast cancer cells. Mol Cell Biochem. 465:199–214. 2020.
27	Carey RM, Kim T, Cohen NA, Lee RJ and Nead KT: Impact of sweet, umami, and bitter taste receptor (TAS1R and TAS2R) genomic and expression alterations in solid tumors on survival. Sci Rep. 12:89372022.
28	Dagan-Wiener A, Di Pizio A, Nissim I, Bahia MS, Dubovski N, Margulis E and Niv MY: BitterDB: Taste ligands and receptors database in 2019. Nucleic Acids Res. 47:D1179–D1185. 2019.
29	Meyer H, Bolarinwa A, Wolfram G and Linseisen J: Bioavailability of apigenin from apiin-rich parsley in humans. Ann Nutr Metab. 50:167–172. 2006.
30	Hostetler GL, Ralston RA and Schwartz SJ: Flavones: Food sources, bioavailability, metabolism, and bioactivity. Adv Nutr. 8:423–435. 2017.
31	Zhang J, Liu D, Huang Y, Gao Y and Qian S: Biopharmaceutics classification and intestinal absorption study of apigenin. Int J Pharm. 436:311–317. 2012.
32	Birt DF, Walker B, Tibbels MG and Bresnick E: Anti-mutagenesis and anti-promotion by apigenin, robinetin and indole-3-carbinol. Carcinogenesis. 7:959–963. 1986.
33	Imran M, Gondal TA, Atif M, Shahbaz M, Qaisarani TB, Mughal MH, Salehi B, Martorell M and Sharifi-Rad J: Apigenin as an anticancer agent. Phytother Res. 34:1812–1828. 2020.
34	Ashrafizadeh M, Bakhoda MR, Bahmanpour Z, Ilkhani K, Zarrabi A, Makvandi P, Khan H, Mazaheri S, Darvish M and Mirzaei H: Apigenin as tumor suppressor in cancers: Biotherapeutic activity, nanodelivery, and mechanisms with emphasis on pancreatic cancer. Front Chem. 8:8292020.
35	Ujiki MB, Ding XZ, Salabat MR, Bentrem DJ, Golkar L, Milam B, Talamonti MS, Bell RH Jr, Iwamura T and Adrian TE: Apigenin inhibits pancreatic cancer cell proliferation through G2/M cell cycle arrest. Mol Cancer. 5:762006.
36	King JC, Lu QY, Li G, Moro A, Takahashi H, Chen M, Go VLW, Reber HA, Eibl G and Hines OJ: Evidence for activation of mutated p53 by apigenin in human pancreatic cancer. Biochim Biophys Acta. 1823:593–604. 2012.
37	Strouch MJ, Milam BM, Melstrom LG, McGill JJ, Salabat MR, Ujiki MB, Ding XZ and Bentrem DJ: The flavonoid apigenin potentiates the growth inhibitory effects of gemcitabine and abrogates gemcitabine resistance in human pancreatic cancer cells. Pancreas. 38:409–415. 2009.
38	Lee SH, Ryu JK, Lee KY, Woo SM, Park JK, Yoo JW, Kim YT and Yoon YB: Enhanced anti-tumor effect of combination therapy with gemcitabine and apigenin in pancreatic cancer. Cancer Lett. 259:39–49. 2008.
39	Nagtegaal ID, Odze RD, Klimstra D, Paradis V, Rugge M, Schirmacher P, Washington KM, Carneiro F and Cree IA: The 2019 WHO classification of tumours of the digestive system. Histopathology. 76:182–188. 2020.
40	Allred DC, Harvey JM, Berardo M and Clark GM: Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol. 11:155–168. 1998.
41	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
42	Singh N, Shaik FA, Myal Y and Chelikani P: Chemosensory bitter taste receptors T2R4 and T2R14 activation attenuates proliferation and migration of breast cancer cells. Mol Cell Biochem. 465:199–214. 2020.
43	Cao SS and Zhen YS: Potentiation of antimetabolite antitumor activity in vivo by dipyridamole and amphotericin B. Cancer Chemother Pharmacol. 24:181–186. 1989.
44	Hebenstreit D, Fang M, Gu M, Charoensawan V, van Oudenaarden A and Teichmann SA: RNA sequencing reveals two major classes of gene expression levels in metazoan cells. Mol Syst Biol. 7:4972011.
45	Wagner GP, Kin K and Lynch VJ: A model based criterion for gene expression calls using RNA-seq data. Theory Biosci. 132:159–164. 2013.
46	He J, Ning C, Wang Y, Huang H, Ge Y, Liu J and Jiang Y: Natural plant flavonoid apigenin directly disrupts Hsp90/Cdc37 complex and inhibits pancreatic cancer cell growth and migration. J Functional Foods. 18:10–21. 2015.
47	Lieber M, Mazzetta J, Nelson-Rees W, Kaplan M and Todaro G: Establishment of a continuous tumor-cell line (panc-1) from a human carcinoma of the exocrine pancreas. Int J Cancer. 15:741–747. 1975.
48	Drucker BJ, Marincola FM, Siao DY, Donlon TA, Bangs CD and Holder WD Jr: A new human pancreatic carcinoma cell line developed for adoptive immunotherapy studies with lymphokine-activated killer cells in nude mice. In Vitro Cell Dev Biol. 24:1179–1187. 1988.
49	Lambert A, Gavoille C and Conroy T: Current status on the place of FOLFIRINOX in metastatic pancreatic cancer and future directions. Therap Adv Gastroenterol. 10:631–645. 2017.
50	Margulis E, Slavutsky Y, Lang T, Behrens M, Benjamini Y and Niv MY: BitterMatch: Recommendation systems for matching molecules with bitter taste receptors. J Cheminform. 14:452022.
51	Melstrom LG, Salabat MR, Ding XZ, Milam BM, Strouch M, Pelling JC and Bentrem DJ: Apigenin inhibits the GLUT-1 glucose transporter and the phosphoinositide 3-kinase/Akt pathway in human pancreatic cancer cells. Pancreas. 37:426–431. 2008.
52	Wu DG, Yu P, Li JW, Jiang P, Sun J, Wang HZ, Zhang LD, Wen MB and Bie P: Apigenin potentiates the growth inhibitory effects by IKK-β-mediated NF-κB activation in pancreatic cancer cells. Toxicol Lett. 224:157–164. 2014.
53	Li Q, Yang G, Feng M, Zheng S, Cao Z, Qiu J, You L, Zheng L, Hu Y, Zhang T and Zhao Y: NF-kappaB in pancreatic cancer: Its key role in chemoresistance. Cancer Lett. 421:127–134. 2018.
54	Kashyap P, Shikha D, Thakur M and Aneja A: Functionality of apigenin as a potent antioxidant with emphasis on bioavailability, metabolism, action mechanism and in vitro and in vivo studies: A review. J Food Biochem. 46:e139502022.
55	Deyme L, Barbolosi D and Gattacceca F: Population pharmacokinetics of FOLFIRINOX: A review of studies and parameters. Cancer Chemother Pharmacol. 83:27–42. 2019.
56	Brierley JD, Gospodarowicz MK, Wittekind C, et al: The TNM classification of malignant tumours 8. Oxford: Wiley Blackwell; 2017